Ciraparantag
|  | |
| Clinical data | |
|---|---|
| Routes of administration | Intravenous | 
| ATC code | None | 
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Onset of action | 10 min | 
| Duration of action | 24 hours | 
| Identifiers | |
| 
 | |
| Synonyms | PER977 N1,N1′-[Piperazine-1,4-diylbis(propane-1,3-diyl)]bis-L-argininamide | 
| CAS Number | 1438492-26-2 | 
| PubChem (CID) | 71576543 | 
| ChemSpider | 33427375 | 
| UNII | U2R67KV65Q | 
| Chemical and physical data | |
| Formula | C22H48N12O2 | 
| Molar mass | 512.71 g·mol−1 | 
| 3D model (Jmol) | Interactive image | 
| 
 | |
| 
 | |
Ciraparantag (INN/USAN, or aripazine) is a drug under investigation as an antidote for a number of anticoagulant (anti-blood clotting) drugs, including factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), dabigatran, low molecular weight heparins and unfractionated heparin.[1][2]
Mechanism of action
According to in vitro studies, the substance binds directly to anticoagulants via hydrogen bonds from or to various parts of the molecule:[1]
| Hydrogen bonds | Rivaroxaban | Apixaban | Edoxaban | Dabigatran | Heparins | 
|---|---|---|---|---|---|
| Guanidine part |  |  |  |  | |
| α-Amino group |  |  |  |  | |
| Amide nitrogen |  |  |  | ||
| Amide oxygen |  |  | 
Chemical properties
Ciraparantag consists of two L-arginine units connected with a piperazine containing linker chain.[1]
See also
Other anticoagulant antidotes
References
This article is issued from Wikipedia - version of the 12/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.